Robert Mahoney - Comera Life Chief Officer
| CMRADelisted Stock | USD 0.66 0.01 1.54% |
Insider
Robert Mahoney is Chief Officer of Comera Life Sciences
| Age | 58 |
| Phone | 617 871 2101 |
| Web | https://comeralifesciences.com |
Comera Life Management Efficiency
The company has return on total asset (ROA) of (1.1935) % which means that it has lost $1.1935 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (16.2902) %, meaning that it created substantial loss on money invested by shareholders. Comera Life's management efficiency ratios could be used to measure how well Comera Life manages its routine affairs as well as how well it operates its assets and liabilities.Comera Life Sciences currently holds 775.05 K in liabilities with Debt to Equity (D/E) ratio of 0.16, which may suggest the company is not taking enough advantage from borrowing. Comera Life Sciences has a current ratio of 2.1, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Comera Life until it has trouble settling it off, either with new capital or with free cash flow. So, Comera Life's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Comera Life Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Comera to invest in growth at high rates of return. When we think about Comera Life's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Melissa Tosca | Kiora Pharmaceuticals | N/A | |
| Lauren White | C4 Therapeutics | N/A | |
| John Castle | Monte Rosa Therapeutics | 53 | |
| Eddie Sullivan | SAB Biotherapeutics | 58 | |
| LLM JD | Rezolute | 63 | |
| Brian Strem | Kiora Pharmaceuticals | 44 | |
| Christopher Roenfeldt | Forte Biosciences | N/A | |
| Walt Esq | Indaptus Therapeutics | 63 | |
| Abhinav Shukla | Shattuck Labs | ||
| Jennifer Champoux | Monte Rosa Therapeutics | N/A | |
| Casi DeYoung | Shattuck Labs | 53 | |
| Justin Trojanowski | Tempest Therapeutics | 36 | |
| Christine MBA | SAB Biotherapeutics | 68 | |
| Neelesh MD | Prelude Therapeutics | N/A | |
| Natalie Holles | Third Harmonic Bio | 51 | |
| Nathanael Gray | C4 Therapeutics | N/A | |
| Peggy Scherle | Prelude Therapeutics | 62 | |
| RAC Sakai | Tempest Therapeutics | N/A | |
| Ajim CFA | Monte Rosa Therapeutics | 47 | |
| Cameron Shaw | Virax Biolabs Group | 37 | |
| MD MBA | Shattuck Labs | 65 | |
Management Performance
| Return On Equity | -16.29 | |||
| Return On Asset | -1.19 |
Comera Life Sciences Leadership Team
Elected by the shareholders, the Comera Life's board of directors comprises two types of representatives: Comera Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Comera. The board's role is to monitor Comera Life's management team and ensure that shareholders' interests are well served. Comera Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Comera Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jeffrey Hackman, Pres Chairman | ||
| MSPH MD, Ex COO | ||
| David Soane, CoFounder Board | ||
| BS CLP, Chief Officer | ||
| Michael CPA, Ex CFO | ||
| Robert Mahoney, Chief Officer |
Comera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Comera Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -16.29 | |||
| Return On Asset | -1.19 | |||
| Operating Margin | (15.82) % | |||
| Current Valuation | 9.96 M | |||
| Shares Outstanding | 30.74 M | |||
| Shares Owned By Insiders | 51.33 % | |||
| Shares Owned By Institutions | 2.70 % | |||
| Number Of Shares Shorted | 281.55 K | |||
| Price To Sales | 43.28 X | |||
| Revenue | 633.1 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Comera Pink Sheet
If you are still planning to invest in Comera Life Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Comera Life's history and understand the potential risks before investing.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |